Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus

被引：84

作者：

Ständer S. ^{[1
,3
]}

Reinhardt H.W. ^{[2
]}

Luger T.A. ^{[1
]}

机构：

[1] Abteilung für Klinische Neurodermatologie, Klinik und Poliklinik für Hautkrankheiten, Universitätsklinikum Münster

[2] Stiefel Laboratorium GmbH, Offenbach

[3] Abteilung für Klinische Neurodermatologie, Klinik und Poliklinik für Hautkrankheiten, Universitätsklinikum Münster, 48149 Münster

来源：

Der Hautarzt | 2006年 / 57卷 / 9期

关键词：

Cannabinoid receptors; Endocannabinoids; Lichen simplex; Prurigo; Pruritus;

D O I：

10.1007/s00105-006-1180-1

中图分类号：

学科分类号：

摘要：

Background. Chronic, therapy-resistant pruritus often fails to respond to standard measures so new therapeutic approaches are needed. Recently, the expression of cannabinoid receptors on cutaneous sensory nerve fibers was described, so cannabinoid agonists seem a rational therapeutic option for pruritus. Patients. In an open application observation 22 patients with prurigo, lichen simplex and pruritus applied an emollient cream containing N-palmitoyl ethanolamine (PEA). Results. In 14/22 patients a good antipruritic effect could be documented. The average reduction in itch was 86.4%. The therapy was well-tolerated by all patients; neither burning burn nor contact dermatitis was observed. Conclusions. Topical cannabinoid agonists represent an new effective and well-tolerated therapy for refractory itching of various origins. Creams with a higher concentration may be even more effective with broader indications. © Springer Medizin Verlag 2006.

引用

页码：801 / 807

页数：6

共 20 条

[1]

Berdyshev E.V., Boichot E., Germain N., Et al., Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells, Eur J Pharmacol, 330, pp. 231-240, (1997)

[2]

Bouaboula M., Rinaldi M., Carayon P., Et al., Cannabinoid-receptor expression in human leukocytes, Eur J Biochem, 214, pp. 173-180, (1993)

[3]

Devane W.A., Dysarz III F.A., Johnson M.R., Et al., Determination and characterization of a cannabinoid receptor in rat brain, Mol Pharmacol, 34, pp. 605-613, (1988)

[4]

Di Marzo V., Bisogno T., De Petrocellis L., Et al., Cannabimimetic fatty acid derivatives: The anandamide family and other endocannabinoids, Curr Med Chem, 6, pp. 721-744, (1999)

[5]

Dvorak M., Watkinson A., McGlone F., Rukwied R., Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin, Inflamm Res, 52, pp. 238-245, (2003)

[6]

Facci L., Dal Toso R., Romanello S., Et al., Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide, Proc Natl Acad Sci USA, 92, pp. 3376-3380, (1995)

[7]

Gallily R., Breuer A., Mechoulam R., 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice, Eur J Pharmacol, 406, (2000)

[8]

Kemeny L., Comparative study of S236 cream and hydrocortisone 1% in patients with atopic dermatitis, JAAD, 52, (2005)

[9]

Klegeris A., Bissonnette C.J., McGeer P.L., Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor, Br J Pharmacol, 139, pp. 775-786, (2003)

[10]

Lambert D.M., Vandevoorde S., Jonsson K.O., Fowler C.J., The palmitoylethanolamide family: A new class of anti-inflammatory agents?, Curr Med Chem, 9, pp. 663-674, (2002)

← 1 2 →